VASOPRESSIN INJECTION, USP SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

VASOPRESSIN

Pieejams no:

FRESENIUS KABI CANADA LTD

ATĶ kods:

H01BA01

SNN (starptautisko nepatentēto nosaukumu):

VASOPRESSIN (ARGIPRESSIN)

Deva:

20UNIT

Zāļu forma:

SOLUTION

Kompozīcija:

VASOPRESSIN 20UNIT

Ievadīšanas:

INTRAMUSCULAR

Vienības iepakojumā:

1ML

Receptes veids:

Prescription

Ārstniecības joma:

PITUITARY

Produktu pārskats:

Active ingredient group (AIG) number: 0106469001; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

1998-07-02

Produkta apraksts

Prescribing Information - Vasopressin Injection, USP
Page 1 of 9_ _
PRESCRIBING INFORMATION
PR
VASOPRESSIN INJECTION, USP
Vasopressin Injection
Sterile Solution
20 USP units / mL
Synthetic
For Intramuscular (IM) or Subcutaneous (SC) Injection
Antidiuretic Agent
Fresenius Kabi Canada Ltd.
165 Galaxy Blvd, Suite 100
Toronto, ON M9W 0C8
Date of Initial Authorization:
OCT 03, 1994
Date of Revision:
MAR 28, 2022
Submission Control Number: 255357
Prescribing Information - Vasopressin Injection, USP
Page 2 of 9_ _
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
03/2022
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
03/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..................................................................................................2
TABLE OF CONTENTS
..................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................................4
1
INDICATIONS
..................................................................................................................4
1.1
Pediatrics.............................................................................................................
4
1.2
Geriatrics
.............................................................................................................
4
2
CONTRAINDICATIONS......................................................................................................4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
....................................................................4
4
DOSAGE AND ADMINISTRATION
.......................................................................................5
4.1
Dosing Considerations
...........................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
...............................................